Saladax Develops First-Ever Rapid Test for an Antipsychotic Drug Using a Single Drop of Blood to Aid Psychiatrists in the Treatment of Schizophrenia
5.9.2019 16:30:00 EEST | Business Wire | Press release
Saladax Biomedical today announced that its MyCare Insite Clozapine Test is now CE marked for use on the MyCare Insite. The MyCare Insite Clozapine Test is the first and only rapid point-of-care test CE marked to aid mental health professionals in the treatment and monitoring of patients with schizophrenia.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190905005085/en/
The MyCare Insite Clozapine Test delivers accurate and precise clozapine blood levels comparable to laboratory results. Psychiatrists need immediate information to make informed decisions during a patient visit. The MyCare Insite Clozapine Test addresses this unmet medical need by providing answers in only six minutes. Clinicians, in consultation with their patients, can use these results to make real-time adjustments to better manage their patients.
"Mental health professionals have very few tools to aid in patient treatment; as a result, patients are suffering. The MyCare Insite Clozapine Test provides clinicians a first of its kind device. The test is evidence of how Saladax is once again setting new standards for innovation in the treatment and monitoring of patients," said Dr. Salvatore Salamone, CEO and Founder of Saladax Biomedical. "We are changing psychiatry with a single drop of blood.”
ABOUT PSYCHOSIS
Psychosis is a condition that affects the way your brain processes information. It causes you to lose touch with reality. Psychotic disorders, like schizophrenia, involve psychosis that usually affects you for the first time in the late teen years or early adulthood. Young people are especially at risk, but doctors don’t know why.
ABOUT THE MyCARE INSITE CLOZAPINE TEST
The MyCare Insite Clozapine Test is intended for the in vitro quantitative measurement of clozapine in human capillary finger blood using the MyCare Insite.
ABOUT SALADAX
Founded in 2004, Saladax Biomedical, Inc. is a privately held company headquartered as an anchor tenant at Ben Franklin TechVentures® located on Lehigh University’s campus in Bethlehem, PA.
Saladax develops rapid blood tests for point-of-care and for laboratory analysers for use in psychiatry and oncology. The Saladax MyCare Psychiatry line provides drug levels for greater insight into patient adherence and possible causes of treatment failures. These tests enable psychiatrists to more accurately assess adherence and better adjust medication dosing. Saladax believes that truly personalized medicine can only exist when the right drug is taken at the right dose. Our diagnostic reagent kits are distributed worldwide and are pending approval in the United States. Saladax is ISO 13485:2016 certified.
For more information, visit Saladax.com or MyCareTests.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190905005085/en/
Contact information
Saladax Biomedical, Inc.
Salvatore Salamone, Ph.D., 610-419-6731
ssalamone@saladax.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Study Reveals the True Environmental Impact of Periodontal Disease – And What You Can Do About It4.6.2026 15:33:00 EEST | Press release
Today P&G Oral Care announces the release of a new, first-of-its kind LCA study published in the Journal of Dentistry finds managing advanced periodontal disease can be associated with up to ~10× higher environmental impact compared with maintaining periodontal health through at-home prevention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260601115251/en/ Oral-B iO9 Black The peer-reviewed paper, titled “Quantifying the Environmental Impact Potential from Periodontal Health to Disease: Findings from a Life Cycle Assessment Study,” for the first time quantifies the environmental burden associated with the presence of periodontal disease, its progression and the associated clinical care. It was developed by sustainability and oral health experts in collaboration with Procter & Gamble (P&G). The ISO 14040/14044–compliant research applies a whole-system life cycle assessment (LCA) lens to oral healthcare, quantifying environm
Corpay Cross-Border Named the Official FX Supplier of Vålerenga Fotball AS4.6.2026 15:30:00 EEST | Press release
Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into an agreement with Vålerenga Fotball AS to become their Official Foreign Exchange (FX) Supplier. Through this partnership, Corpay Cross-Border will deliver comprehensive FX risk management solutions to support Vålerenga Fotball AS’s operations. In addition, its award-winning platform will enable the club to manage global payments seamlessly through a single point of access. “Corpay Cross-Border is proud to be named the Official FX Supplier of Vålerenga Fotball AS,” said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “This partnership reinforces Corpay’s position as a leading provider of corporate payments and currency risk management solutions within professional football, while giving us a strong platform to expand our brand and business in Norway. We look forward to supporting the club as they pursue success in the Eliteser
CloudInteract and Red Kite Launch Joint Delivery Partnership for Agentic AI Voice on Amazon Connect and Pega4.6.2026 15:19:00 EEST | Press release
CloudInteract, the Amazon Connect and agentic AI specialist, and Red Kite, the Pega delivery partner, today announced a joint delivery partnership to bring autonomous AI voice agents to enterprises using the Pega and Amazon Connect platforms. The partnership debuts a working solution on Amazon Connect, Amazon Bedrock, that can be seen at PegaWorld® in Las Vegas, 7–9 June 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604645983/en/ Initial use cases span healthcare, financial services, insurance, government, and BPO. The companies will demonstrate a healthcare appointment booking call at PegaWorld, but the same architecture applies to any regulated environment where AI interactions must be executed within governed workflows, using real-time customer context, policy, and decisioning. This ensures AI interactions don’t stop at conversation or data access—they result in completed, governed service outcomes. The demonstr
Visa and Brale Explore Private Stablecoin Settlement for Institutional Payments4.6.2026 15:00:00 EEST | Press release
Visa (NYSE: V) today announced a collaboration with Brale to explore stablecoin-based settlement using SBC, a U.S. dollar-backed stablecoin issued by Brale, on the Canton Network. The proof of concept will evaluate how privacy-enabled blockchain infrastructure can support faster, more programmable settlement while helping financial institutions and payment companies maintain control over the visibility of sensitive settlement transaction data. Visa began enabling stablecoin settlement in 2021 and continues to expand its capabilities, allowing VisaNet obligations to be settled using supported stablecoins. A central focus of this collaboration is the Canton Network’s privacy architecture. As stablecoin adoption grows, financial institutions are assessing how they can use blockchain-based settlement while meeting strict privacy and compliance requirements. Unlike many public blockchain networks, Canton is designed to allow participants to transact on shared infrastructure while limiting t
The Open Group Publishes Industrial Advanced Nuclear™ Consortium’s Inaugural Application Scenarios Whitepaper4.6.2026 15:00:00 EEST | Press release
The Open Group, the vendor-neutral technology standards organization, today announced the publication of the Industrial Advanced Nuclear™ Consortium (IANC) Application Scenarios Whitepaper, setting out how advanced nuclear technologies can be deployed to deliver reliable, low‑carbon heat and power across heavy industry. The Whitepaper, driven by IANC, an industrial end-user-driven organization, represents a significant step forward in the role of nuclear energy in relation to energy transition. Outlining real-world use cases where Small Modular Reactors (SMRs) and Micro Modular Reactors (MMRs) could be integrated directly into industrial operations, it focuses on sectors that are amongst the most difficult to decarbonize, including: Offshore energy Refining and petrochemicals Mining Energy‑intensive manufacturing. Developed by leading industrial end users, the Whitepaper provides a consolidated view of the operational requirements, energy demands, and constraints facing these sectors.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom